Valuation: Karyopharm Therapeutics Inc.

Market Cap 44.42M 38.48M 36.02M 32.88M 61.83M 4.24B 62.88M 423M 165M 2.12B 167M 163M 7.07B P/E 2026 *
-0.48x
P/E 2027 * -0.77x
Enterprise Value 44.42M 38.48M 36.02M 32.88M 61.83M 4.24B 62.88M 423M 165M 2.12B 167M 163M 7.07B EV / Sales 2026 *
0.33x
EV / Sales 2027 * 0.25x
Free-Float
95.32%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Karyopharm Therapeutics Inc.

1 day+7.14%
1 week+6.60%
Current month+9.38%
1 month-79.69%
3 months-75.69%
6 months-68.13%
Current year-71.47%
1 week 1.88
Extreme 1.88
2.18
1 month 1.8
Extreme 1.8
10.3
Current year 1.8
Extreme 1.8
10.99
1 year 1.8
Extreme 1.8
10.99
3 years 1.8
Extreme 1.8
29.25
5 years 1.8
Extreme 1.8
220.95
10 years 1.8
Extreme 1.8
444.15
Manager TitleAgeSince
Chief Executive Officer 58 03/05/2021
Director of Finance/CFO 55 03/01/2025
Chief Tech/Sci/R&D Officer - 01/04/2023
Director TitleAgeSince
Director/Board Member 62 01/01/2013
Director/Board Member 61 01/04/2013
Director/Board Member 78 03/10/2013
Date Insider Type Main position Quantity % Market Cap.
28/07/26 Sell

Executive/Senior Manager

-189 0.0008%
14/05/26 Sell

Controller/Auditor

-53 0.0002%
17/02/26 Sell

Executive/Senior Manager

378 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
+7.14%+6.60%-46.70%-91.62% 44.42M
-1.37%+4.97%+41.56%+0.50% 80.69B
+2.55%+13.07%+2.40%+30.48% 51.22B
+0.49%+2.17%+22.60%+177.89% 49.58B
+2.87%+11.29%-46.98%-47.72% 45.5B
-1.56%+1.03%+56.03%-24.22% 30.6B
-0.39%+2.23%+54.45%+84.81% 24.64B
+1.27%+9.85%+131.89%-39.60% 23.88B
-1.80%+11.10%+4.71%+196.74% 21.59B
-5.89%+34.09%-0.99%+792.56% 17.09B
Average +0.20%+164.04%+21.90%+107.98% 34.48B
Weighted average by Cap. -0.07%+270.75%+25.37%+76.68%

Financials

2026 *2027 *
Net sales 134M 116M 108M 98.99M 186M 12.76B 189M 1.27B 498M 6.38B 502M 491M 21.3B 175M 151M 142M 129M 243M 16.66B 247M 1.66B 650M 8.33B 656M 641M 27.81B
Net income -118M -102M -95.71M -87.37M -164M -11.26B -167M -1.12B -439M -5.63B -443M -434M -18.8B -105M -90.88M -85.06M -77.65M -146M -10.01B -149M -998M -390M -5.01B -394M -385M -16.71B
Net Debt - -
Logo Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer. It is developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO is also marketed for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including myelofibrosis, endometrial cancer and multiple myeloma. The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Employees
228
Date Price Change Volume
11/08/26 $2.100 +7.14% 1,954,363
10/08/26 $1.960 -7.55% 1,795,726
07/08/26 $2.120 +8.72% 1,792,750
06/08/26 $1.950 +2.09% 1,189,123
05/08/26 $1.910 -2.55% 2,376,615
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.960USD
Average target price
6.400USD
Spread / Average Target
+226.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KPTI Stock